Changes of thrombocytes functional activity and vascular wall anti-thrombogenious activity in bronchial asthmatic patients under systemic glucocorticosteroids therapy

Abstract

Bronchial asthma (BA) is one of the most crucial problems of the modern medicine. Today there is a number of patients who need systemic glucocorticosteroids (GCS) therapy. Inspite of the fact that systemic GCS have been used for bronchial asthmatic patients’ treatment for more than 40 years, a lot of these drugs actions to human organism have been vague.
The aim of this study was to investigate changes of thrombocytes functional activity and vascular wall anti-thrombogenious activity in bronchial asthmatic patients under systemic glucocorticosteroids therapy.
Sixty-two asthmatic patients were examined during three days (exacerbation period) and after 2—2.5 weeks (abating exacerbation period) of their inpatient treatment. All the patients were divided into three groups: who did not receive systemic GCS (the 1-st group), who first received systemic GCS (the 2-nd group) and who have been treated with systemic GCS for more than 1 year (the 3-rd group). Parameters of haemostasis and vascular wall anti-thrombogenious activity were studied, (cuff test).
The trial carried out revealed that the disorders of thrombocytes functional activity and vascular wall anti-thrombogenious activity were more intensive during bronchial asthma exacerbation under long-term therapy with systemic GCS.
The data obtained allow considering the problem of disaggrerants and drugs which improve vascular wall anti-thrombogenious activity to be involved in the treatment for bronchial asthmatics who receive systemic GCS.